Florian Schmitzberger

Dr. Florian Schmitzberger is a distinguished molecular immunologist and biotechnologist with a focus on engineering proteins for cutting-edge human cancer immunotherapies.

Currently serving as the Principal Scientist of Molecular Immunology at Matterhorn Biosciences, Dr. Schmitzberger leads pioneering protein engineering research to advance MR1 reactive T cell receptor (TCR) T cell based immuno-oncology cell therapy.

His illustrious career includes spearheading innovative research projects in both the biotechnology industry and academia, where he thrives on devising inventive solutions for biological system engineering and establishing protein engineering platforms and teams.

With extensive hands-on experience in various realms including protein engineering, structural biology, experimental protein biochemistry, biophysical protein analyses, protein X-ray crystallography, yeast genetics, and live cell fluorescence microscopy, Dr. Schmitzberger brings a wealth of expertise to any scientific endeavor.

His academic journey saw him attain a Doctor of Philosophy (PhD) in Biochemistry from the renowned University of Cambridge, complemented by a Bachelor of Science in Chemistry from the University of Vienna with the highest honors.

Dr. Schmitzberger has contributed significantly to the scientific community through his authored publications stemming from his research at esteemed institutions such as Harvard Medical School, Karolinska Institute, and IMP Vienna, where he also engaged in teaching protein sciences.

Beyond his current role at Matterhorn Biosciences, Dr. Schmitzberger has held pivotal positions including Principal Scientist of Molecular Immunology at Ridgeline Discovery, Principal Scientist of Antibody Rational Design at Ichnos Sciences, and Scientist II of Protein Engineering & Biochemistry at AgenTus Therapeutics.

His academic affiliations include being a Visiting Lecturer at Universit\u00e4t Salzburg, a Research Associate at University of Duisburg-Essen, a Postdoctoral Researcher at Research Institute of Molecular Pathology (IMP), a Research Fellow at Harvard Medical School, and a PhD student at University of Cambridge.

Additionally, he gained industry experience through an internship at Sandoz. Dr. Florian Schmitzberger's dedication to advancing molecular immunology and biotechnology through groundbreaking research and leadership roles cements his position as a key figure in the scientific community.